Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model

被引:54
|
作者
Tao, D
Barba-Spaeth, G
Rai, U
Nussenzweig, V
Rice, CM
Nussenzweig, RS
机构
[1] Rockefeller Univ, Lab Virol & Infect Dis, New York, NY 10021 USA
[2] NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10016 USA
[3] NYU, Sch Med, Dept Pathol, Michael Heidelberger Div, New York, NY 10016 USA
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2005年 / 201卷 / 02期
关键词
D O I
10.1084/jem.20041526
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The yellow fever vaccine 17D (17D) is safe, and after a single immunizing dose, elicits long-lasting, perhaps lifelong protective immunity. One of the major challenges facing delivery of human vaccines in underdeveloped countries is the need for multiple injections to achieve full efficacy. To examine 17D as a vector for microbial T cell epitopes, we inserted the H-2K(d)-restricted CTL epitope of the circumsporozoite protein (CS) of Plasmodium yoelii between 17D nonstructural proteins NS2B and NS3. The recombinant virus, 17D-Py, was replication competent and stable in vitro and in vivo. A single subcutaneous injection of 10(5) PFU diminished the parasite burden in the liver by similar to70%. The high level of protection lasted between 4 and 8 wk after immunization, but a significant effect was documented even 24 wk afterwards. Thus, the immunogenicity of a foreign T cell epitope inserted into 17D mimics some of the remarkable properties of the human vaccine. Priming with 17D-Py followed by boosting with irradiated sporozoites conferred sterile immunity to 90% of the mice. This finding indicates that the immune response of vaccine-primed individuals living in endemic areas could be sustained and magnified by the bite of infected mosquitoes.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 50 条
  • [1] 17D Yellow Fever Virus Vaccine
    Monath, Thomas P.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2013, 89 (06): : 1225 - 1225
  • [2] 17D Yellow Fever Virus Vaccine Response
    Edupuganti, Srilatha
    Mulligan, Mark J.
    Eidex, Rachel B.
    Cetron, Martin
    Marfin, Anthony A.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2013, 89 (06): : 1226 - 1227
  • [3] CONSTRUCTION OF A RECOMBINANT YELLOW FEVER 17D CLONING VECTOR
    Kaltenborn, Z. P.
    Vogt, J.
    Spies, G.
    McElrath, M. J.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (01) : 172 - 173
  • [4] Yellow Fever 17D Vaccine Safety and Immunogenicity in the Elderly
    Monath, Thomas P.
    Cetron, Martin S.
    McCarthy, Karen
    Nichols, Richard
    Archambault, W. Tad
    Weld, Leisa
    Bedford, Philip
    [J]. HUMAN VACCINES, 2005, 1 (05): : 207 - 214
  • [5] Antibody response 17D yellow fever vaccine in Ghanaian infants
    Osei-Kwasi, M
    Dunyo, SK
    Koram, KA
    Afari, EA
    Odoom, JK
    Nkrumah, FK
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2001, 79 (11) : 1056 - 1059
  • [6] Does yellow fever 17D vaccine protect against melanoma?
    Mastrangelo, G.
    Krone, B.
    Fadda, E.
    Buja, A.
    Grange, J. M.
    Rausa, G.
    de Vries, E.
    Koelmel, K. F.
    [J]. VACCINE, 2009, 27 (04) : 588 - 591
  • [7] Neurovirulence tests of three 17D yellow fever vaccine strains
    Minor, Philip D.
    [J]. BIOLOGICALS, 2011, 39 (03) : 167 - 170
  • [8] VACCINATION BY SCARIFICATION WITH A COMBINED 17D YELLOW FEVER AND VACCINIA VACCINE
    DICK, GWA
    HORGAN, ES
    [J]. JOURNAL OF HYGIENE, 1952, 50 (03) : 376 - 383
  • [9] Is a dose of 17D vaccine in the current context of Yellow Fever enough?
    Estofolete, Cassia Fernanda
    Nogueira, Mauricio Lacerda
    [J]. BRAZILIAN JOURNAL OF MICROBIOLOGY, 2018, 49 (03) : 683 - 684
  • [10] Stability-related studies on 17D yellow fever vaccine
    Perraut, R
    Girault, G
    Moreau, JP
    [J]. MICROBES AND INFECTION, 2000, 2 (01) : 33 - 38